06:05:50 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-02-14 Bokslutskommuniké 2023
2023-11-15 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-16 Kvartalsrapport 2023-Q1
2023-05-11 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-23 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-16 Kvartalsrapport 2022-Q1
2022-05-13 Ordinarie utdelning NYKD 0.00 NOK
2022-05-12 Årsstämma 2022
2022-03-31 Bokslutskommuniké 2021
2021-12-22 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning NYKD 0.00 NOK
2021-05-05 Årsstämma 2021
2021-04-21 Bokslutskommuniké 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-07 Split NYKD 1:5
2020-07-06 Extra Bolagsstämma
2020-05-12 Kvartalsrapport 2020-Q1
2020-04-22 Extra Bolagsstämma

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Nykode Therapeutics är verksamma inom bioteknik. Bolaget är idag specialiserade inom forskning och utveckling av immunologiska terapier och vacciner. Lösningarna används huvudsakligen för behandling av patienter med cancersjukdomar samt övriga allvarliga hälsotillstånd som kräver långsiktig behandling. Störst verksamhet återfinns inom den europeiska marknaden.
2022-06-13 08:35:00
Oslo, Norway, June 13, 2022 - Nykode Therapeutics ASA (Euronext Growth (Oslo):
NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and
development of vaccines and novel immunotherapies, announced today the
appointment of Klaus Edvardsen, M.D., Ph.D., as Chief Development Officer. The
appointment will take effect on July 1, 2022.

Chief Executive Officer of Nykode Therapeutics, Michael Engsig, said: "I am very
pleased to welcome Klaus to Nykode Therapeutics' executive management team.
Klaus brings tremendous international leadership experience in directing
successful drug development programs at renowned biopharmaceutical companies. As
Nykode's candidates continue to advance through the clinical, we are eager for
Klaus' significant contributions to our drug development strategies."

"I am very excited to be joining Nykode Therapeutics," said Klaus Edvardsen,
M.D., Ph.D. "Nykode has developed a unique platform technology and has entered
into some impressive collaborations and partnerships with world-class
biopharmaceutical companies. With its strong development pipeline, Nykode has
built a great momentum on its quest to develop game changing medicines across an
expanding range of therapeutic areas and I look forward to joining the team."

Klaus Edvardsen joins Nykode from CureVac where he held a similar role as Chief
Development Officer. Other previous roles include Senior Vice President and Head
of Global Oncology Development of Merck KGaA, where he led early- and late-stage
global oncology development. Prior to these roles, he served as Senior Vice
President and Head of Global Medicines Development Oncology at AstraZeneca,
where he was responsible for the overall development strategy for oncology and
hematology programs. Klaus Edvardsen also held leadership roles at both
GlaxoSmithKline and Genmab in medicines development within various therapeutic
areas. Klaus Edvardsen holds a M.D. degree as well as a Ph.D. in cancer biology
from University of Copenhagen.


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen specific immune responses
and eliciting efficacious clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive interim efficacy and safety results from its Phase II
trial for the treatment of cervical cancer